Home
>
National Drug Code (NDC)
>
CHLORDIAZEPOXIDE HYDROCHLORIDE and CLIDINIUM BROMIDE
CHLORDIAZEPOXIDE HYDROCHLORIDE and CLIDINIUM BROMIDE - 67877-186-01 - (CHLORDIAZEPOXIDE HYDROCHLORIDE and CLIDINIUM BROMIDE)
Drug Information of CHLORDIAZEPOXIDE HYDROCHLORIDE and CLIDINIUM BROMIDE
| Product NDC: | 67877-186 |
| Proprietary Name: | CHLORDIAZEPOXIDE HYDROCHLORIDE and CLIDINIUM BROMIDE |
| Non Proprietary Name: | CHLORDIAZEPOXIDE HYDROCHLORIDE and CLIDINIUM BROMIDE |
| Active Ingredient(s): | 5; 2.5 mg/1; mg/1 & nbsp; CHLORDIAZEPOXIDE HYDROCHLORIDE and CLIDINIUM BROMIDE |
| Administration Route(s): | ORAL |
| Dosage Form(s): | CAPSULE |
| Coding System: | National Drug Codes(NDC) |
Labeler Information of CHLORDIAZEPOXIDE HYDROCHLORIDE and CLIDINIUM BROMIDE
| Product NDC: | 67877-186 |
| Labeler Name: | Ascend Laboratories, LLC |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | |
| Marketing Category: | UNAPPROVED DRUG OTHER |
| Start Marketing Date: | 20100122 |
Package Information of CHLORDIAZEPOXIDE HYDROCHLORIDE and CLIDINIUM BROMIDE
| Package NDC: | 67877-186-01 |
| Package Description: | 100 CAPSULE in 1 BOTTLE (67877-186-01) |
NDC Information of CHLORDIAZEPOXIDE HYDROCHLORIDE and CLIDINIUM BROMIDE
| NDC Code | 67877-186-01 |
| Proprietary Name | CHLORDIAZEPOXIDE HYDROCHLORIDE and CLIDINIUM BROMIDE |
| Package Description | 100 CAPSULE in 1 BOTTLE (67877-186-01) |
| Product NDC | 67877-186 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | CHLORDIAZEPOXIDE HYDROCHLORIDE and CLIDINIUM BROMIDE |
| Dosage Form Name | CAPSULE |
| Route Name | ORAL |
| Start Marketing Date | 20100122 |
| Marketing Category Name | UNAPPROVED DRUG OTHER |
| Labeler Name | Ascend Laboratories, LLC |
| Substance Name | CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE |
| Strength Number | 5; 2.5 |
| Strength Unit | mg/1; mg/1 |
| Pharmaceutical Classes | Benzodiazepine [EPC],Benzodiazepines [Chemical/Ingredient],Anticholinergic [EPC],Decreased Parasympathetic Acetylcholine Activity [PE],GI Motility Alteration [PE],Digestive/GI System Activity Alteration [PE],Cholinergic Antagonists [MoA] |
